This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n10http://localhost/temp/predkladatel/
n16http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n8http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11310%2F14%3A10288480%21RIV15-MSM-11310___/
n5http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11310%2F14%3A10288480%21RIV15-MSM-11310___
rdf:type
n12:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1021/ac502727s
dcterms:description
Enhanced fucosylation has been suggested as a marker for serologic monitoring of liver disease and hepatocellular carcinoma (HCC). We present a workflow for quantitative site-specific analysis of fucosylation and apply it to a comparison of hemopexin (HPX) and complement factor H (CFH), two liver-secreted glycoproteins, in healthy individuals and patients with liver cirrhosis and HCC. Label-free LC-MS quantification of glycopeptides derived from these purified glycoproteins was performed on pooled samples (2 pools/group, 5 samples/pool) and complemented by glycosidase assisted analysis using sialidase and endoglycosidase F2/F3, respectively, to improve resolution of glycoforms. Our analysis, presented as relative abundance of individual fucosylated glycoforms normalized to the level of their nonfucosylated counterparts, revealed a consistent increase in fucosylation in liver disease with significant site- and protein-specific differences. We have observed the highest microheterogeneity of glycoforms at the N187 site of HPX, absence of core fucosylation at N882 and N911 sites of CFH, or a higher degree of core fucosylation in CFH compared to HPX, but we did not identify changes differentiating HCC from matched cirrhosis samples. Glycosidase assisted LC-MS-MRM analysis of individual patient samples prepared by a simplified protocol confirmed the quantitative differences. Transitions specific to outer arm fucose document a disease-associated increase in outer arm fucose on both bi- and triantennary glycans at the N187 site of HPX. Further verification is needed to confirm that enhanced fucosylation of HPX and CFH may serve as an indicator of premalignant liver disease. The analytical strategy can be readily adapted to analysis of other proteins in the appropriate disease context. Enhanced fucosylation has been suggested as a marker for serologic monitoring of liver disease and hepatocellular carcinoma (HCC). We present a workflow for quantitative site-specific analysis of fucosylation and apply it to a comparison of hemopexin (HPX) and complement factor H (CFH), two liver-secreted glycoproteins, in healthy individuals and patients with liver cirrhosis and HCC. Label-free LC-MS quantification of glycopeptides derived from these purified glycoproteins was performed on pooled samples (2 pools/group, 5 samples/pool) and complemented by glycosidase assisted analysis using sialidase and endoglycosidase F2/F3, respectively, to improve resolution of glycoforms. Our analysis, presented as relative abundance of individual fucosylated glycoforms normalized to the level of their nonfucosylated counterparts, revealed a consistent increase in fucosylation in liver disease with significant site- and protein-specific differences. We have observed the highest microheterogeneity of glycoforms at the N187 site of HPX, absence of core fucosylation at N882 and N911 sites of CFH, or a higher degree of core fucosylation in CFH compared to HPX, but we did not identify changes differentiating HCC from matched cirrhosis samples. Glycosidase assisted LC-MS-MRM analysis of individual patient samples prepared by a simplified protocol confirmed the quantitative differences. Transitions specific to outer arm fucose document a disease-associated increase in outer arm fucose on both bi- and triantennary glycans at the N187 site of HPX. Further verification is needed to confirm that enhanced fucosylation of HPX and CFH may serve as an indicator of premalignant liver disease. The analytical strategy can be readily adapted to analysis of other proteins in the appropriate disease context.
dcterms:title
Quantification of Fucosylated Hemopexin and Complement Factor H in Plasma of Patients with Liver Disease Quantification of Fucosylated Hemopexin and Complement Factor H in Plasma of Patients with Liver Disease
skos:prefLabel
Quantification of Fucosylated Hemopexin and Complement Factor H in Plasma of Patients with Liver Disease Quantification of Fucosylated Hemopexin and Complement Factor H in Plasma of Patients with Liver Disease
skos:notation
RIV/00216208:11310/14:10288480!RIV15-MSM-11310___
n3:aktivita
n19:I
n3:aktivity
I
n3:cisloPeriodika
21
n3:dodaniDat
n13:2015
n3:domaciTvurceVysledku
n16:4576462
n3:druhVysledku
n7:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n8:predkladatel
n3:idSjednocenehoVysledku
41057
n3:idVysledku
RIV/00216208:11310/14:10288480
n3:jazykVysledku
n9:eng
n3:klicovaSlova
glycoproteins; cirrhosis; human serum; chronic hepatitis; protein glycosylation; n-glycans; alpha-fetoprotein; glycan database search; site-specific glycoforms; hepatocellular-carcinoma patients
n3:klicoveSlovo
n4:site-specific%20glycoforms n4:hepatocellular-carcinoma%20patients n4:cirrhosis n4:human%20serum n4:glycan%20database%20search n4:protein%20glycosylation n4:chronic%20hepatitis n4:glycoproteins n4:n-glycans n4:alpha-fetoprotein
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[1CA864DE4ED9]
n3:nazevZdroje
Analytical Chemistry
n3:obor
n11:CB
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
5
n3:rokUplatneniVysledku
n13:2014
n3:svazekPeriodika
86
n3:tvurceVysledku
Sanda, Miloslav Wu, Jing Benicky, Julius Goldman, Radoslav Pompach, Petr
n3:wos
000344510200032
s:issn
0003-2700
s:numberOfPages
8
n5:doi
10.1021/ac502727s
n10:organizacniJednotka
11310